Posted on

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

Calgary, AB – TheNewswire – June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO ) , ( OTC:IBOGF ) and ( FSE:JC4) (“ UI ” or the “ Company ”) a life sciences company with a mission to transform addiction treatment using medicalized ibogaine and a global licensing model is pleased to announce that Nick Karos, CEO will present at the H.C. Wainwright 1 st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond.  The event is a hybrid online and in person event scheduled for June 27, 2022.

About H.C. Wainwright

H.C. Wainwright & Co is one of the oldest and most trusted names in corporate finance in the USA providing investment banking, corporate advisory, research, and analysis covering sectors including Healthcare & Life Sciences, Mining, Cleantech, Shipping & Maritime and Technology.

H.C. Wainwright hosts a robust calendar of conferences and events in the Healthcare sector.  More information and registration for the 1 st Annual Mental Health Conference can be found here .

Nick Karos CEO of Universal Ibogaine commented “H.C. Wainwright is a leader in the space and could be a strong strategic partner in our ongoing corporate finance roadmap.  The opportunity to tell our story to this audience is another important step in developing the awareness around brand and offering.

Correction Notice June 13 Blue Digital Media

In UI’s June 13, 2022 News Release it was stated that stock options to be granted to investor relations advisory firm Blue Digital Media would vest one-third at the end of each month in the 3 month term of service. Under TSXV Exchange Policy 4.4 Security Based Compensation, stock options for investor relations firms must vest quarterly over a 12 month period with the first vesting for 25% of the options at 3 months,25% at 6 months, 25% at 9 months and the final 25% at 12 months.

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:  

Investor Relations: Dugan Selkirk, Investor Relations Manager 

dugan.selkirk@universalibogaine.com 

Related Links  https://universalibogaine.com

Posted on

Universal Ibogaine Retains Shayne Nyquvest As Capital Markets Advisor

Universal Ibogaine Retains Shayne Nyquvest As Capital Markets Advisor

Calgary, AB – April 29, 2022 – Universal Ibogaine Inc. (TSXV:IBO, OTCQB:IBOGF and FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.

Mr. Nyquvest has extensive capital markets experience, with over 40 years involvement in aiding companies strategic fund-raising activities, in the mining, cannabis and other emerging industries.  He served as the former Executive Vice-President of investment banking firm Mackie Research Capital (where he worked from June 2015 to July 2018) and a was founding member of Canaccord Genuity Group, where he worked as a Senior Investment Advisor from 1993 to 2013. 

Mr. Nyquvest cofounded UI in early 2018, after personally seeing the transformational effects and potential of ibogaine, and was involved in UI’s early stage development until mid-2021.  His vision has been to see this innovative, plant-based treatment adopted by the mainstream medical community as a solution to helping break the opioid epidemic and other addictions.

Nick Karos, UI CEO noted “we are pleased to have Shayne re-engaged in our strategic, business development goals.  He has an extensive network in the investment community, and was instrumental in UI’s early stage financing and research activities.  We continue to advance our planned Health Canada clinical trials application for the use of ibogaine in opioid use disorder, and expect to provide additional updates on this in the near future.”

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. 

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:

Investor Relations: Dugan Selkirk, IR Manager

dugan.selkirk@universalibogaine.com

Posted on

Universal Ibogaine Advises Of Departure Of Marilyn Mauritz From Board Of Directors

Universal Ibogaine Advises Of Departure Of Marilyn Mauritz From Board Of Directors

Calgary, AB – April 21, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the UI Board of Directors to pursue other opportunities. 

The Board of Directors would like to thank Marilyn for her significant contribution to the Company during her tenure as a Director and wish her well in her future endeavours. 

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.  

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager 

dugan.selkirk@universalibogaine.com 

Related Links https://universalibogaine.com

Posted on

Universal Ibogaine Provides Update On Kelburn Recovery Center Operations

Universal Ibogaine Provides Update On Kelburn Recovery Center Operations

Calgary, AB – April 7, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (“Kelburn”) due to an on-site flooding issue. 

Kelburn is UI’s addiction treatment site operating near Winnipeg, Manitoba, and which experienced abnormally high winter snowfall conditions, resulting in high current groundwater levels arising from spring melt conditions.  Kelburn is currently assessing options for continuation of in-process patient treatment, and remediation of damages, which will fall under Kelburn’s property and business interruption insurance coverage, subject to policy limits.  The timing for remediation and ultimate re-opening of operations at Kelburn is not determinable, but will likely require a minimum of 2 to 3 months. 

Nick Karos (CEO) noted “this is of course an unfortunate unforeseen event, and our first priority is to ensure the continuity of ongoing care of our patient group.   The extent of damage will hopefully be contained to a portion of the basement, and allow us to resume on-site operations in a reasonable time frame.” 

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.  

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws.

Posted on

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Calgary, AB – April 5, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF and FSE: JC4) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the “FSE”) under the ticker symbol “JC4”.  UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker symbol IBOGF. 

The FSE is the largest stock exchange in Germany and is the premiere European destination for Canadian Venture companies looking to build exposure and liquidity with the European market.  The FSE facilitates advanced electronic trading, settlement and information systems allowing it to meet the growing requirements of cross-border trading.

Global Addiction and the Overdose Crisis

According to an August 4, 2021, World Health Organization report, worldwide approximately 500,000 deaths annually can be attributed to drug use, with more than 70% related to opioids. 

“The number of opioid overdoses has increased in recent years in several countries, in part due to the increased use of opioids in the management of chronic pain and increasing use of highly potent opioids appearing on the illicit drug market.

In the United States of America (USA) the number of people dying from opioid overdose increased by 120% between 2010 and 2018, and two-thirds of opioid-related overdose deaths in 2018 in the USA involved synthetic opioids, including fentanyl and its analogues.

During the COVID-19 pandemic, a further substantial increase in drug overdose deaths was reported in the USA, primarily driven by rapid increases in overdose deaths involving synthetic opioids.”

What is ibogaine?

Ibogaine is a plant derived neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state and has demonstrated particular effectiveness in treating opioid use disorder in many countries.  When applied according to a strict safety protocol, including a medically supervised setting, ibogaine appears to eliminate the most painful symptoms of opioid withdrawal and can provide a several month window free of drug cravings.  Dr. Alberto Sola, co-founder and member of the Board of Directors of Universal Ibogaine, has administered more ibogaine treatments than any other doctor in the world at an independent clinic (of which he is a partner) in Cancun, Mexico. 

The Universal Ibogaine Mission

Universal Ibogaine is a Canadian company which holds the global licensing rights to the ibogaine based addiction treatment protocol developed by Dr. Alberto Sola.  UI is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the ibogaine treatment protocol for opioid use disorder(s).  Upon eventual completion of the trial and Health Canada approval, UI intends to license the protocol to a global network of addiction treatment clinics.  Ibogaine can be very effective for long term addiction cessation when combined with an aftercare treatment program.  Universal Ibogaine operates an addiction treatment facility in Winnipeg, where it is intends to develop best in class addiction treatment programs built around evidence based treatments and nuovo modalities. 

Universal Ibogaine CEO Nick Karos commented “the FSE listing is a key piece of our capital markets and investor relations strategy.  We have recently commenced trading on the OTCQB Exchange in the USA, and interest in the UI story is growing in Europe and Germany in particular.  Germany has a history of innovation and leadership with an emerging market and interest in psychedelic medicines.”

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. 

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager 

dugan.selkirk@universalibogaine.com

Medical Contact: Hirpal Hundial, Director – Clinical Services

hirpal.hundial@universalibogaine.com  

Posted on

Universal Ibogaine To Participate In The 2022 Virtual Growth Conference

Universal Ibogaine To Participate In The 2022 Virtual Growth Conference

Presented by Maxim Group LLC and hosted by M-Vest on

March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT

Calgary, Canada – March 24, 2022 — [Universal Ibogaine] [TSXV:IBO and OTCQB:IBOGF], a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, announced today that Company CEO Nick Karos has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th   from 9:00 a.m. – 5:00 p.m. EDT.

Sign up here to access the presentation

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

Click Here to Reserve your seat

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol globally through future licensing agreements.  UI is concurrently developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre in Winnipeg, Manitoba that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager dugan.selkirk@universalibogaine.com

Chief Executive Officer:  Nick Karos, CEO nick.karos@admin_universalibogaine

Posted on

Universal Ibogaine Expands Research Team With Julie Dumouchel, Director Of Clinical Trials

Universal Ibogaine Expands Research Team With Julie Dumouchel, Director Of Clinical Trials

Calgary, Alberta – March 23, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce the key strategic addition of Julie Dumouchel as Director of Clinical Trials.  Universal Ibogaine is working towards a planned clinical trial with Health Canada to prove the safety and efficacy of ibogaine for the disruption of opioid addiction.  UI owns the global licensing rights for the ibogaine treatment protocol developed by Dr. Alberto Sola, UI Board Member and one of the founders of the Clear Sky Recovery Clinic which has operated an addiction treatment centre in Cancun, Mexico since 2007.  Dr Sola has safely administered over 3,700 ibogaine treatments, more than any other doctor in the world.

Julie Dumouchel brings 25 years in the pharmaceutical industry, where she has held various clinical research roles, developing a deep understanding of the drug development process. Julie is passionate about clinical operations and the drug development process.  Her experience leading strong research teams to advance clinical trials while navigating changing regulations will augment UI’s planned business platforms of drug development and clinical service delivery.

As Director of Clinical Trials, Julie Dumouchel will lead the design, planning and execution of ibogaine clinical trials and related projects. As a pharmaceutical industry executive, Julie has had roles in Clinical Research Organizations such as Quintiles and Santé Cannabis, biotechs including MethylGene (TSX: MYG), Canopy Health Innovations and large pharmaceutical companies including Schering-Plough, Merck, and Bayer.  In 2018, as the Director of Clinical Operations at Canopy Health Innovation, Julie assembled a clinical operations team to advance key trials using medical cannabis while navigating an environment of complex and changing regulations. In her role at Santé Cannabis, Julie led the team responsible for all aspects of clinical trials (medical cannabis and psychedelics), from planning to reporting while maintaining high quality standards.

Nick Karos, UI CEO stated, “We welcome Julie to our team, and look forward to her guidance as we continue to work with our CRO research partners to finalize our Clinical Trial Application for Health Canada.  This announcement demonstrates we are making progress towards our CTA and confident in our path forward.”

About Universal Ibogaine

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol globally through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre in Winnipeg, Manitoba that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager 

dugan.selkirk@universalibogaine.com 

Media Contact: Cathy Fernandes, Director – Marketing & Communications cathy.fernandes@universalibogaine.com  

Posted on

Universal Ibogaine To Present At Otc Virtual Investor Event

Universal Ibogaine To Present At Otc Virtual Investor Event

Universal Ibogaine Inc. to Webcast Live at OTC Markets VirtualInvestorConferences.com March 10th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Calgary, AB Canada, March 08, 2022 — Universal Ibogaine (OTCQB:IBOGF TSXV:IBO FSE:JC4), a life sciences company based in Canada, focused on transforming the addiction treatment industry through the medical use of the plant medicine ibogaine, today announced that Nick Karos Name, Chief Executive Officer, will present live at OTC Markets VirtualInvestorConferences.com on March 10th, 2022.

DATE: March 10th, 2022

TIME: 12:00 PM EST

LINK: https://bit.ly/3LRhCdu

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Event attendees will also be able to schedule 1 on 1 meetings with the Investor Relations team which will take place on Friday March 11, Monday March 14, and Tuesday March 15.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

About Universal Ibogaine


Universal Ibogaine is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. 

About Virtual Investor Conferences

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

CONTACTS:

Universal Ibogaine

Dugan Selkirk

Investor Relations Manager

1-855-426-4246

dugan.selkirk@universalibogaine.com

Virtual Investor Conferences

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com

Posted on

Universal Ibogaine Announces Approval Of Trading On OTCQB Venture Market

Universal Ibogaine Announces Approval Of Trading On Otcqb Venture Market

Calgary, AB – February 28, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the OTCQB Venture Market (the “OTCQB”) under the ticker “IBOGF”.  UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO. 

The UI common shares trading in the United States have also been approved for DTC eligibility.

The OTCQB Venture Market is for early stage and developing U.S. and international companies, which are current in their reporting and undergo an annual verification and management certification process.  Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com

Universal Ibogaine CEO Nick Karos stated: “Accessing the vast USA market of retail and institutional investors  through the OTC platform will provide our current and future shareholders enhanced liquidity and expanded global exposure for the Company, which will assist with our future financing and growth plans.  We look forward to working with the OTC Markets Group, as the USA is a key future addiction treatment market for us, with over 100,000 lives lost to opioid overdose last year alone.”   

OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, it connects a diverse network of broker-dealers that provide liquidity and execution services. It enables investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for investors.


About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS


‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur. The forward-looking statements and information are based
on certain key expectations ‎and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect
and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎


For further information:


Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com


Media Contact: Cathy Fernandes, Director – Marketing & Communications
cathy.fernandes@universalibogaine.com

Posted on

Universal Ibogaine Signs Memorandum Of Understanding With Osoyoos Indian Band

Universal Ibogaine Signs Memorandum Of Understanding With Osoyoos Indian Band

Calgary, AB – February 10, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to advise it has entered a Memorandum of Understand (the “MOU”) with Osoyoos Indian Band Development Corporation  (“OIBDC”). 

Osoyoos Indian Band

Osoyoos Indian Band is a world leader in indigenous business.  OIBDC has generated hundreds of millions of dollars of revenue on its lands through tourism, leasing and construction related endeavors, joint ventures and partnerships with globally recognized brands such as Hyatt and Jackson-Triggs.  The Osoyoos Indian Band has 540 members and its territory spans over 32000 acres of the warmest lands in Canada located in the Okanagan valley of British Columbia, between Osoyoos and Oliver. 

MOU Objectives

The MOU has as its objective, participation of both organizations for purpose and profit, to construct an ibogaine centered detox clinic and holistic aftercare treatment centre. The partners will act as collaborators in bridging economic and social models that respect Indigenous ways while leveraging Western scientific practices.  Partnership opportunities may include leasing or joint venture with possibilities to convert existing space or new construction.  The development timeline will coincide with the planned Health Canada approval process of the Universal Ibogaine treatment protocol. 

Chief Ian Campbell – Chairman Universal Ibogaine

Chief Ian Campbell of the Squamish Nation and UI Board Chair shared “The primary focus for Universal Ibogaine is to bring this life saving medicine to those who need it as quickly as possible.  This potential partnership between UI and the Osoyoos Indian Band demonstrates what is possible when we work together towards a solution.”   

Chief Clarence Louie – Osoyoos Indian Band

Clarence Louie is a globally recognized indigenous leader and has served as the elected Chief of the Osoyoos Indian Band for close to 40 years. He is a sought-after speaker and holder of innumerable awards, including an Order of Canada and membership in the Canadian Business Hall of Fame.  Chief Clarence stated, “We are pleased with the opportunity to partner on this venture and bring opportunities for economic inclusion and deep healing for many people to our lands.”   

Nick Karos – CEO Universal Ibogaine

Nick Karos, recently appointed CEO of Universal Ibogaine added “We are excited for this developing relationship.  The Osoyoos Indian Band is one of the most proactive and forward-looking groups we have had the opportunity to engage with.  We have a big job ahead, and partners like Osoyoos Indian Band add huge credibility to our mission and can aid in diversifying our business opportunities and the planned ultimate deployment of the ibogaine addiction treatment protocol”. 

Mike Campol – COO Osoyoos Indian Band Development Corporation

“The opioid epidemic is a public health emergency.  We have to do better than opioid substitution therapy.  What we have here is an opportunity to be part of a transformation in the way that society treats those who suffer, views plant medicine, and understands indigenous culture.  We are pleased to see where this collaboration can take us.”  


About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS
THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS


‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur. The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI. Although UI believes that the expectations
and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.


Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect
and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎


For further information:


Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com


Media Contact: Cathy Fernandes, Director – Marketing & Communications
cathy.fernandes@universalibogaine.com